Nalbuphine tablets for chronic cough in pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) by a doctor.
- You have had a chronic cough for at least 8 weeks before the screening visit.
- Your cough severity is rated as at least 2 on a standard scale (mild or more).
- Your lung function tests show a forced vital capacity (FVC) of at least 40% of predicted, and a diffusing capacity (DLCO) of at least 25% of predicted.
- If you take antifibrotic medications (like nintedanib, pirfenidone, or nerandomilast), your dose has been stable for at least 6 weeks.
- You have not had a respiratory infection or hospitalization for breathing problems in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.